Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.

A Ibáñez(Hospital Universitari Germans Trias i Pujol), B Clotet, Mònica Balaguer, Lı́dia Ruiz(IrsiCaixa), J Colomer, Cristóbal Richart(Universitat Rovira i Virgili), Miguel Camafort(Hospital Clínic de Barcelona), F Vidal, M. Cervantes, Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Joaquim Peraire(Instituto de Salud Carlos III), C Villalonga

PubMed

April 1, 1997

Cited by 1

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

|JAMA|2016|1.4k

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

|The Lancet|2019|1k

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19

|JAMA|2021|728

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

|The Lancet HIV|2021|110

Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort

|Antiviral Research|2015|95